Today: 30 June 2026
Browse Category

LSE:PRU.L 7 January 2026 - 11 February 2026

Prudential plc share price ends week higher as PRU buyback and BoE rate bets shape the next move

Prudential plc share price ends week higher as PRU buyback and BoE rate bets shape the next move

London, Feb 7, 2026, 09:27 — The market has closed. Prudential plc notched a 0.5% gain Friday, ending the session around 1,182 pence and clawing back a slice of Thursday’s decline. The insurer kept up its buyback activity in the market. Now, as the London market goes quiet for the weekend, traders look ahead to Monday, with rates and repurchase plans still dominating watch lists.
Prudential plc share price today: buyback update hits after Thursday slide

Prudential plc share price today: buyback update hits after Thursday slide

London, February 6, 2026, 09:23 GMT — Regular session Prudential plc shares were down 0.1% at 1,174 pence by 09:23 GMT on Friday after the insurer reported another round of share repurchases. The stock has traded between 1,153.5p and 1,174p so far in the session, and Prudential said it bought back 494,445 shares on Thursday. https://www.investing.com/equities/prudential-historical-data https://www.investegate.co.uk/announcement/rns/prudential--pru/transaction-in-own-shares/9413590
6 February 2026
Prudential plc stock slips as $1.2bn buyback kicks off; investors eye March results

Prudential plc stock slips as $1.2bn buyback kicks off; investors eye March results

London, Jan 7, 2026, 09:26 GMT — Regular session Prudential plc shares slipped in early London trade on Wednesday, pulling back from a fresh 52-week high after the insurer launched a new share buyback. Prudential was down 1.4% at 1,179 pence, after opening at 1,205 and hitting an intraday low of 1,176; the stock touched 1,213 pence on Tuesday. London South East

Stock Market Today

  • CELZ Jumps 252% as Creative Medical Technology Drops Equity Offer
    June 30, 2026, 12:50 PM EDT. Shares of Creative Medical Technology Holdings (NASDAQ:CELZ) shot up 252% Tuesday after the company pulled its June 25 S-1 for an equity and warrant deal. CELZ said it had not issued any shares under the canceled filing. Trading was heavy, hitting 146.1 million shares-almost 40 times its 3.7 million shares outstanding. The shelved offer would have meant 3.05 million new shares and warrants for another 6.09 million. CEO Timothy Warbington said they decided not to go ahead with the fundraising plan. Biotech ETFs didn't move much, pointing to a CELZ-specific jump. Still, analysts say cash remains tight, with limited room for rounds of regulatory approvals after December 2027.
Go toTop